Treatment of Solid Papillary Carcinoma of Breast with Evidence of Invasion in HER2-Positive Early Invasive Breast Cancer

Clinical Scenario

This protocol applies to patients with HER2-positive early invasive breast cancer — specifically solid papillary carcinoma of the breast with evidence of invasion — who have completed primary treatment and are being considered for adjuvant systemic therapy, provided cardiac function meets the required threshold.

Patient Eligibility Criteria

HER2-positive early invasive breast cancer confirmed on pathology
Left ventricular ejection fraction above 55% on pre-treatment cardiac assessment
No prior history of documented congestive heart failure

Cardiac function must be formally assessed before commencing this regimen. Patients with a left ventricular ejection fraction of 55% or less, or a history of documented congestive heart failure, are not eligible.

Approach (partial overview)

Adjuvant treatment with a HER2-directed targeted agent — Trastuzumab (Herceptin) — is indicated following surgery, chemotherapy, and radiotherapy. The complete dosing schedule, number of planned doses, and monitoring requirements are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

When applicable, trastuzumab (Herceptin) should be given at 3-week intervals for one year or until disease recurrence (whichever is the shorter period), as an adjuvant treatment to women with HER2-positive early invasive breast cancer following surgery, chemotherapy, and radiotherapy.

An assessment of cardiac function should be made before starting treatment with trastuzumab and it should not be offered to women who have any of the following: a left ventricular ejection fraction (LVEF) of 55% or less; a history of documented congestive heart failure.

View source ↗